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Abstract  
Reduced graphene oxide - iron oxide quantum dots (QDs) with intrinsic photoluminescent 
and superparamagnetic properties were synthesized through a green, hydrothermal method 
that simultaneously reduced and shattered graphene nanosheets to form the dots. The 
structure, morphology, properties and cell viability of these QDs were investigated. The QDs 
emitted violet light when excited at 320 nm, possessed no residual magnetization upon 
magnetic hysteresis tests, and had low cytotoxicity to healthy cells at low concentrations. The 
suitability of the QDs for fluorescent and magnetic resonance dual-modality imaging was 
shown by in vitro imaging with dermal fibroblast cells and T2 relaxation time. A drug could 
be loaded onto the surface of the QDs, with a loading ratio of drug to QD of 0.31:1. The drug 
achieved a steady but full release from the QDs over 8 h: these drug-loaded QDs could be 
manipulated by an external magnetic stimulation for targeted drug delivery. The potential for 
use as a cancer photothermal therapy was demonstrated by both a rapid, ~50 oC temperature 
increase by a suspension of 100 µg ml-1 of QDs and the photothermal ablation of HeLa cells 
in vitro under near infrared irradiation. The stability of the MGQDs in fetal calf serum was 
shown to improve when an ionic drug was coated on the surface. 
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1. Introduction 
Biomedical technology is undergoing a period of rapid development, and one of the keys to 
this advancement is nanotechnology [1]. Graphene, and its chemically oxidized derivative 
graphene oxide (GO), have been investigated for drug delivery, biosensing, and cancer 
photothermal therapy as they have a large surface area, ample functional groups on the 
surface, photothermal properties and/or low cytotoxicity [2,3]. Iron oxide (IO) nanoparticles 
have also been studied for biomedical purposes [4]. Their superparamagnetic (i.e. they hold 
no residual magnetic force and can be manipulated by external magnetic fields) behavior 
allows for them to be used for targeted therapeutic delivery [5]. They can be imaged in vivo 
by Magnetic Resonance Imaging (M.R.I.), enabling the visualisation of tumors and the 
circulatory system, as well as finding use in magnetic hyperthermia [6,7].  
IO can be deposited onto GO to form GO-IO or reduced graphene oxide (rGO)-IO 
hybrids [8–11] (the chemical deposition may reduce GO to rGO during the synthesis [12]), 
which can combine the interesting aspects of both individual nanoparticles [8–12]. Previous 
work [9,12] has shown that graphene-IO nanoparticles can be used for targeted drug delivery, 
M.R.I., and photothermal therapy; the functional groups of GO or rGO allow for drug loading 
while the superparamagnetic properties of IO enable the hybrids to be used for targeted drug 
delivery using an external magnetic stimulus and M.R.I.. Both graphene [13] and IO [14] 
were shown to absorb near infrared (NIR) light, which was converted into heat for 
photothermal therapy. For instance, GO-IO reduced the cancer cell viability by ~90% by 
using a 2 W cm-2 laser for 5 min [9], and rGO-IO achieved the full ablation of tumours within 
mice within 24 h using a 0.5 W cm-2 laser as the irradiation source [12]. However, no 
intrinsic photoluminescent properties were demonstrated for the graphene – IO nanoparticles 
reported in the literature [11,15,16]. The fluorescent imaging capability of the rGO-IO 
nanoparticles were from dyes (polyfluorene [11] and cyanine [12]) bonded to the nanoparticle 
surface. The photoluminescent properties of the GO-IO were attributed to the bonded 
doxorubicin, which the GO-IO quenched in comparison to free doxorubicin [9]; these 
nanoparticles were approximately 50 – 300 nm in size and did not possess intrinsic 
photoluminescent properties. 
 Quantum dots (QDs) emit a luminescence due to quantum confinement effects [17]. 
Conventionally, QDs were made of compounds like cadmium selenide (CdSe) or cadmium 
telluride (CdTe), but they were found to be cytotoxic during in vitro cell tests due to the 
photolysis release of cadmium ions and the uncoiling of DNA helical strands [18,19]. This 
led to the development of biocompatible carbon-based QDs, with QDs derived from 
carbohydrates [20], nanodiamonds [21], and graphene [22–25]. Graphene QDs (GQDs) can 
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be created by ultrasonication [22], chemical reduction [23], photo-reduction [24], and 
hydrothermal cutting [25]. These carbon QDs emit the same level of luminescence as the 
cadmium QDs, but do not carry the same cytotoxic risk. It has been shown that GQDs could 
enter cells but did not enter the nucleus of stem cells during in vitro tests; they maintained a 
high (80%) viability for neurosphere and pancreas progenitor cells up to 100 µg ml-1 after 72 
h [26], and carboxylated GQDs caused no acute toxicity to rats after 22 days post injection at 
a concentration of 10 mg kg-1 [27]. Carbon QDs can be excreted rapidly from the body after 
being administered through intravenous, intramuscular or subcutaneous injections [28].  
To the authors’ knowledge, biocompatible graphene-based magnetic QDs that are 
intrinsically both superparamagnetic and photoluminescent have not yet been reported. 
Quantum dots with magnetic properties (MQDs) can by synthesized by either doping 
conventional QDs (for example CdSe, or CdTe ) with metal elements like manganese [29], 
nickel [30], or gadolinium [31], or by encasing conventional QDs with IO [32] in silica 
spheres. These MQDs possess the photoluminescent properties of conventional QDs and the 
magnetic properties of the doping agent or the encapsulated IO, but they contain cytotoxic 
compounds such as cadmium selenium or cadmium telluride and are therefore cytotoxic 
without a biocompatible passivation coating [30]. The aim of this work was to synthesize 
magnetic graphene-IO quantum dots (herein MGQDs) as a multifunctional nanosystem for 
fluorescent imaging, M.R.I., targeted drug delivery and photothermal therapy for concurrent 
detection, monitoring and treatment of diseases. The MGQDs were synthesized by depositing 
IO on GO surface, followed by autoclaving to reduce GO into rGO and form the MGQDs. 
Their structure, morphology, cell viability, drug release behavior, fluorescent imaging and 
M.R.I. capabilities and photothermal properties were assessed.  
2. Experimental 
2.1 Materials 
The following chemicals were used as purchased from Sigma Aldrich; sulfuric acid (95-
98%), hydrogen peroxide (29-32% in water), potassium permanganate (97%), sodium nitrate 
(> 99%), ferrous chloride tetrahydrate (> 99%), hydrochloric acid (36.5%), ferric chloride 
hexahydrate (97%), fluorescein sodium, graphite powder (≤ 20 µm), rhodamine B, 
norharmane, lidocaine hydrochloride (> 99%), porcine trypsin (BioReagent), 3-[4,5-
dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) solution (1 mg ml-1 in 
phosphate buffered saline (PBS)), and ethylenediaminetetraacetic acid (EDTA, BioReagent). 
Dulbecco’s modified eagle medium (DMEM, 500 ml, Gibco Invitrogen (Paisley, UK) was 
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used with fetal calf serum (FCS, Advanced Protein Products, Brierley Hill, UK), penicillin 
(100 units ml-1), streptomycin (100 µg ml-1), and fungizone (630 ng ml-1) from Gibco 
Invitrogen (Paisley, UK). Isopropanol alcohol (reagent grade) and PBS tablets (pH = 7.4) 
were acquired from Fisher Scientific UK. 
2.2 Preparation of graphene oxide – iron oxide nanoparticles 
Graphene oxide was synthesized from a modified Hummers method [33] and GO-IO was 
prepared according to methods described in the literature with some modifications [8,34]. 
The freeze-dried GO powder (1 g) was dispersed in 150 ml of distilled water through stirring 
and sonication for 1 h and the pH of the suspension was raised to pH = 8 with the addition of 
ammonium hydroxide NH4OH. Separately, ferrous chloride tetrahydrate FeCl2-4H2O (5.4 g) 
and ferric chloride hexahydrate FeCl3-6H2O (4 g) were dissolved in 135 ml distilled water. 
The GO suspension and the solution of IO precursors were added together, ammonium 
hydroxide was added drop wise until a pH = 10 was reached, and then the mixture was stirred 
for 2 h under a nitrogen atmosphere at ambient temperature. The precipitate, iron oxide 
coated graphene oxide (GO-IO), was washed with distilled water, ethanol and 
dichloromethane to remove residual chemicals, separated from unbound, hydrophobic IO 
precipitate by decanting the GO-IO as the supernatant from an aqueous suspension, before 
being re-dispersed in distilled water (~ 3 mg ml-1) by sonication for 1 h in a Fisherbrand 
sonication bath (230 V, 50-60 Hz). As a control sample, IO was prepared using the same 
method but without the addition of GO. 
2.3 Preparation of reduced graphene oxide-iron oxide quantum dots 
The aqueous GO-IO suspension (~ 3 mg ml-1) was treated in a Parr Series 4000 autoclave at 
200 oC for 10 h (pressure of boiling water at 201 oC = 1.6 MPa) to generate reduced graphene 
oxide-iron oxide quantum dots (namely, MGQDs). The suspension was placed in a dialysis 
bag (Fisher Scientific Biodesign Dialysis tubing, molecular weight cut off = 3.5 kDa) and the 
residual chemicals were allowed to diffuse into the distilled water surrounding the dialysis 
bag [25]. The MGQDs were collected in an aqueous suspension from the dialysis bag and 
lyophilized in a Labconco FreeZone Triad freeze-dryer to be stored as a powder in a 
desiccator. As a control, GO and IO (both with a raised pH of 8) were autoclaved at 200 oC 
for 10 h to produce graphene quantum dots and autoclaved iron oxide (A-IO) for a 
comparison study.  
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2.4 Drug loading onto quantum dots 
Lidocaine hydrochloride (LH) (0.1 mg ml-1) was added to a 100 ml suspension of MGQDs 
(0.1 mg ml-1) under stirring for 48 h. The suspension was centrifuged at 9000 rpm for 1 hour, 
after which the supernatant (containing unbound LH) was removed and the precipitate was 
re-dispersed in water. This process was repeated several times to remove all of the unbound 
LH. The MGQD-LH was then freeze-dried and stored in a desiccator. 
2.5 Characterization  
Transmission electron microscopy (TEM), energy dispersive X-ray spectroscopy (EDS), and 
selected area electron diffraction (SAED) were achieved using a Philips Technai T20 electron 
microscope operating at an accelerating voltage of 200 kV. High resolution TEM (HR-TEM) 
was carried out using a JEOL 2010F field emission gun TEM operating at an accelerating 
voltage of 200 kV. TEM and HR-TEM samples were prepared by evaporating a diluted 
suspension (~ 0.01 mg ml-1) onto a holey amorphous carbon coated copper grid (mesh size = 
400). Electron energy loss spectroscopy (EELS) spectra were acquired on the JEOL 2010F 
using a Gatan image filter in image coupled mode with an energy dispersion of 0.5 eV per 
pixel. Atomic force microscopy (AFM) was carried out on a Veeco Dimension 3100 with 
Olympus AC160TS probes in tapping mode at 0.5 Hz, using a diluted suspension (~ 0.01 mg 
ml-1) evaporated onto a freshly cleaved mica substrate. Dynamic light scattering (DLS) was 
performed on a Brookhaven ZetaPALS (660 nm wavelength), with 3 cycles of 2 min runs on 
suspensions of 1 mg ml-1 MGQD in distilled water.  
X-ray diffraction (XRD) was performed on a Stoe Stadi P with Cu Kα irradiation 
(0.154 nm wavelength), with operating parameters of 40 kV, 35 mA, and a scanning speed of 
1o min-1. Raman spectroscopy between 50-3000 cm-1 with a resolution of 0.5 cm-1 was 
achieved with a Renishaw inVia Raman microscope using a 514.5 nm wavelength laser. 
Fourier transform infrared (FT-IR) spectroscopy between 400-4000 cm-1 with a resolution of 
1 cm-1 was performed on a Perkin Elmer Spectrum 100 with a diamond attenuated total 
reflectance unit. Thermogravimetric analysis (TGA) was implemented on a Perkin Elmer 
Pyris 1 with a nitrogen atmosphere (20 ml min-1) at a heating rate of 5 oC min-1. Inductively 
coupled plasma mass spectrometry (ICP-MS) was carried out using a Spectro-Ciros-Vision 
ICP-Emission Spectrometer. Samples were extracted in 12 ml aqua regia at 150 oC for 30 
min, followed by the addition of 1 ml hydrofluoric acid and stirring at 150 oC for 15 min, and 
were then diluted using distilled water to a total end volume of 50 ml. A Micromeritics 
AccuPyc II 1340 was used to measure the density of the MGQDs, achieved at room 
temperature (24 oC) by using 10 purge cycles and 10 calculation cycles of helium gas.  
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UV-visible light (UV-Vis) spectroscopy of nanoparticle suspensions in distilled water 
(0.3 mg ml-1 concentration) from 200-800 nm with a 1 nm resolution was achieved with a 
Perkin Elmer Lambda 900 spectrometer. Photoluminescence spectroscopy was conducted 
using a Horiba Fluoromax 4 with excitation sources from 300-400 nm and emission readings 
from 360-600 nm with a wavelength resolution of 2 nm. Photoluminescence quantum yield 
measurements used fluorescein sodium in 0.1 NaOH, rhodamine B in ethanol and 0.01% 
HCl, and norharmane in 0.1 M H2SO4 as reference standards. Quantum yield measurements 
were taken by using Equation 1 [35], shown below: 
ɸqd= ɸst× 
Gradqd
Gradst
× 
ηqd 
2
ηst
2                                                          (1) 
where “ɸ” is the fluorescence quantum yield, “Grad” is the gradient of the curve of emission 
versus absorbance, “η” is the refractive index for the solvent used in the solution, and “qd” 
and “st” are quantum dots and the standards used (fluorescein sodium, rhodamine B and 
norharmane). PL lifetime analysis (time correlated single photon counting) was achieved with 
irradiation from a frequency doubled Mira 900 Ti-Sapphire laser (10 W), a single photon 
counting module (Becker and Hickl SPC-830), an electronic trigger (Becker & Hickl GmbH 
PHD-400-N High Speed Photodiode Module), and the emission was detected by an ID 
Quantique ID100-50 single photon detection module. The magnetic hysteresis loop was 
created using a Quantum Design MPMS-XL 5 superconducting quantum interference device 
(SQUID), operating at 37 oC to simulate in vivo conditions and between +/- 20,000 Oe (2 T) 
in 200 Oe intervals. A Siemens Trio TIM 3 Tesla M.R.I. was used to measure the T2 
relaxation times of the MGQDs, with the echo time, TE = 15.2, 30.4, 45.6, 60.8, 76, 91.2, 
106.4, 121.6, 136.8, 152, 167.2 milliseconds and the relaxation time TR = 3000 milliseconds.  
2.6 Cell viability and imaging 
Human skin was obtained with ethical permission from patients undergoing abdominoplasties 
or breast reductions from the Department of Plastics, Burns and Reconstructive Surgery, 
Sheffield Teaching Hospitals. All tissue was collected and used on an anonymous basis under 
a Human Tissue Authority research bank tissue license number 08/H1308/39. 
Dermal fibroblast cells were isolated and cultured, as described previously [36], in 
DMEM at 37 oC and 5% CO2 environment. When the culture was 50% confluent, the cells 
were collected by treating with a trypsin solution for 10 min and centrifuging the cell 
suspension to form a pellet at 1000 rpm for 5 min using a Hettich Rotafix 32A centrifuge. 
Cells were counted, with cells seeded (10,000 per well) in a 48 well plate. Cells were 
incubated overnight in DMEM to allow for cell reattachment, after which the DMEM 
medium was replaced with MGQD suspensions (20, 50, 100, 200, 500 µg ml-1 in DMEM) for 
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6 and 24 h incubation times (each testing iteration was tested in triplicate). At the end of each 
incubation time, cells were washed with PBS and then incubated in fresh DMEM until 72 h 
post-treatment when cells were assessed by the MTT-assay of metabolic activity. Cells were 
incubated for 40 min at 37 oC, after which the formazan salt was eluded by acidified 
isopropanol. The optical densities of the resultant solutions were measured with a plate reader 
at 540 nm with a reference filter of 630 nm (Bio-Tek ELx800). Control samples of untreated 
cells in DMEM were taken as 100% viable, and the optical densities of the MGQD treated 
cells were compared to these values. 
An Olympus CK40 microscope and a Leica TCS SP8 two-photon confocal 
microscope (excitation source 690 nm, emission filter 360 nm) were used for cell imaging. 
For the two-photon fluorescent imaging, the cells were incubated with either 50 µg ml-1 or 
100 µg ml-1 MGQDs for 12 h before the cells were fixed with glutaraldehyde. 
2.7 Drug release from MGQDs 
A 10 ml PBS suspension (37 oC, pH = 7.4) of MGQD-LH (1 mg ml-1 MGQD-LH) was 
inserted into a Spectrum Labs Float-A-Lyzer G2 dialysis tube with pore sizes between 0.1 – 
0.5 kDa. This dialysis tube was floated vertically in a sealed container of pristine PBS 
solution (550 ml, 37 oC, pH = 7.4), with a float at the top and a weight at the end maintaining 
the buoyancy of the dialysis tube just under the surface of the solution. This container was 
placed within a Stuart SI500 bio-incubator, maintained at 37 oC and agitated at 100 rpm. At 
set time points, 3 ml of PBS solution was taken from the outer container (replaced with 3 ml 
of fresh PBS) and analyzed with a Perkin Elmer Lambda 900 (resolution of 1 nm).  The 
acquired spectra were compared to the absorbance values of free LH of known concentration 
(ranging from 0.06 – 1 mg ml-1) in PBS. 
2.8 Photothermal measurements 
The temperature of aqueous suspensions of MGQDs and GQDs (1.5 ml, concentration of 50 
µg ml-1 and 100 µg ml-1) under irradiation from a near-infrared continuous laser (wavelength: 
808 nm; laser power: 2, 5, 7.5 W cm-2) was measured as a function of time. Distilled water 
was studied as a control.  
 Photothermal experiments on HeLa cells incubated with suspensions of MGQDs and 
GQDs were carried out with a near-infrared continuous laser (wavelength: 808 nm; laser 
power: 2.5 W cm-2). HeLa cells were seeded to a density of 5000 cells per well of a 96 well 
culture plate (BD Falcon, U.S.). Cells were incubated at 37 oC in a 5% CO2 atmosphere for 
24 h to allow for reattachment. After incubation, the cell culture medium was replaced by the 
MGQD or GQD suspension (100 µl of cell medium with a 50 µg ml-1 suspension of MGQD 
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or GQD). After 4 h incubation with the QDs, the cells were irradiated by a laser for 20 min or 
30 min. After incubation overnight, the QD suspension medium was removed and the cells 
were washed twice with PBS. To test the viability of the cells after irradiation, 100 µl of 
CCK-8 solution was added to each well and the cells were incubated for 2 h. The optical 
density of the cell solution was read on a microplate reader (Varioskan Flash, Thermo 
Scientific), with measurements taken at 450 nm.  
2.9 Biostability 
MGQD and MGQD-LH were dispersed in distilled water, PBS and FCS at a concentration of 
50 µg ml-1. Suspensions were imaged using a digital camera after predetermined intervals.   
2.10 Statistical analysis 
Statistical analysis (p < 0.05) and graphing were completed through MatLab 2012a software. 
Size analysis of TEM images was conducted through ImageJ software, with 60 separate 
samples taken over several images. 
 
3. Results and discussion 
3.1 Structure 
MGQDs were synthesized by coating the surface of GO with IO using the precursors 
of IO, followed by a hydrothermal treatment to simultaneously reduce GO into rGO and 
shatter the nanosheets to form MGQDs. The synthesis procedure is illustrated in Figure 1. 
Figure 2A shows TEM (A-1 and A-2) and AFM (Fig. 2B, Inset) images of MGQDs. The 
synthesized MGQDs have an average diameter of 41.8 (±8.1) nm from the TEM images, and 
an average diameter of 45.2 (±10.3 nm) and a height of 2.3 nm (±0.07 nm) from AFM. DLS 
results (Fig. 2B) show a mean hydrodynamic diameter of 61.4 nm, with a significant count 
within the 45–90 nm range. It is larger than the average diameters obtained from AFM and 
TEM, which can be accounted for by the presence of larger nanoparticles (i.e. agglomerates) 
in the polydisperse MGQD water suspension [37]. The diameter of the MGQDs is larger than 
hydrothermally reduced GQDs (5–25 nm) previously reported by by other groups [25,38,39], 
but these papers use either a longer hydrothermal treatment time (24 h) [38,39] or an 
additional oxidation procedure to further reduce the size of their GO before the hydrothermal 
treatment [25]. The diameter is, however, similar to that of the GQDs (51.9 nm) prepared by 
the same oxidation and hydrothermal treatment method in our group [40]. 
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Figure 1 Synthesis procedure for magnetic graphene quantum dots (MGQDs).  
 
 
 
 
Figure 2 (A) TEM images of MGQDs, showing that the QDs are approximately 40-50 nm in 
diameter, (B) DLS size analysis of MGQD aqueous suspension, showing the majority of MGQDs are 
within the 45-90 nm diameter range; (Inset) AFM image of MGQDs, showing an average height of 
2.3 nm and an average width of 45.2 nm. (C) EDS spectrum of the MGQD presented in Figure 2 (A-
2), showing a composition of carbon, oxygen, and iron; (inset) the SAED pattern of the MGQD, 
confirming the presence of iron oxide. 
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The MGQDs are identifiable in both the conventional and high resolution TEM 
images in dark contrast (Figure 2A1-2A2, 3A) on the amorphous carbon film support due to 
the presence of high density IO (4.9 – 5.2 g cm-3 for magnetite [41]) within the MGQDs as 
well as mass-thickness contrast, similar to the identification of IO on GO-IO reported in the 
literature [9]. Under HR-TEM, a region of magnetite (Fe3O4) within an MGQD (Figure 3B) 
can be identified by the (400) lattice spacing ~0.227 nm [42], with a similar region of 
magnetite in Figure 3C, 3D and 3E identifiable by the (220) lattice spacing of ~0.345 nm 
[42,43]. A region of folded graphene (or rGO) layers can also be seen in Figure 3D and 3E by 
the (002) lattice spacing of ~0.347 nm and the wrinkled structure similar to the literature 
[44,45]. The region of graphene in Figure 3D and 3E contrasts in structure to the amorphous 
carbon support on the TEM grid, shown in Figure S1 of Supplemental Information and also 
present in the upper section of Figure 3C. The region of IO in Figure 3D and 3E appears to be 
on the surface of the graphene region. Figure 3F shows a layer-structured nanoparticle with a 
darker layer on top of a lighter layer, which may be interpreted as a layer of dense IO coated 
on top of a graphene surface. The inset of Figure 3G shows our proposed structure of MGQD, 
with IO coated on top of the folded graphene sheets and with some edges of graphene sheets 
uncovered due to the fracture of IO-graphene during the hydrothermal reduction. As the 
residual IO precursors and IO were removed from GO-IO nanoparticles before hydrothermal 
treatment, we expect the amount of individual A-IO particles present in the MGQDs to be 
minimal, if any. 
As described previously, the average thickness of the MGQDs from AFM is 2.3 nm, 
which is thicker than the reported thickness of graphene (0.37 nm [46]), rGO (~0.8 nm [47]) 
or the GQDs prepared using the same hydrothermal reduction method (1.5 nm [40]). This 
suggests that the IO coating on both sides of the MGQD surface is likely 0.8 – 1.9 nm thick; 
however, we do not exclude the possibility of the presence of some residual thicker 
nanoparticles in the MGQD. IO growth on GO was reported to be smaller than pristine IO 
growth due to the dispersed nucleation of Fe3+ by the oxygen functional groups (C=O) of GO 
[48], and a similar effect may have occurred during the synthesis of the IO on the GO-IO 
followed by reduction of GO into rGO during hydrothermal cutting. 
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Figure 3 (A-F) HR-TEM images of MGQDs, showing (A) a cluster of MGQDs on amorphous carbon 
film support showing distinguishable individual MGQDs, (B) a region of IO on graphene (rGO), (C) a 
region of IO on carbon film support, (D-E) a region of IO on graphene, (F) an example of the layered 
structure of the MGQD, showing a graphene base with IO layer on top; (G) EELS spectrum of 
MGQDs, showing a composition of oxygen and iron, (Inset: Scheme of the proposed structure of the 
MGQDs). 
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Figure 4 (A) XRD traces, (B) Raman spectra (C) FT-IR spectra and (D) TGA curves of GO, IO, GO-
IO, GQDs, A-IO, and MGQDs. 
The composition of the MGQD in Figure 2A-2 can be seen in the EDS spectrum in 
Figure 2C, which confirms the presence of iron (0.72, 6.42, and 7.08 keV) [49,50]. The 
oxygen (0.54 keV) was from the IO and the residual oxygenated groups in the 
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hydrothermally reduced GO while carbon (0.3 keV) was from the rGO and carbon-coated 
copper grids (0.94, 8.06, and 8.92 keV) [49,51]. The SAED pattern (Figure 2C, Inset) has the 
ring patterns associated with (220) and (104) diffraction peaks of magnetite and hematite (α-
Fe2O3) respectively [52,53]. The EELS spectrum of a thin layer-structured nanoparticle 
acquired from HR-TEM (Figure 3G) confirms the presence of IO on the MGQD, as shown by 
the oxygen K-edge peaks at 529, 540, and 561 eV and the iron L2,3 peaks at 708 and 722 eV 
[54]. 
The results from XRD (Figure 4A) confirm that the MGQDs are characterized by 
both rGO and a mixture of magnetite, maghemite (γ-Fe2O3), and hematite. GO has been 
oxidized from graphite and is largely exfoliated (weak (002) peak at 2θ = 10.6o) [33]. IO is 
crystalline, with a (220) peak at 2θ = 30.7o, a strong (311) peak at 2θ = 35.5o, a (400) peak at 
2θ = 43.2o, a (422) peak at 2θ = 57.2o, and a (511) peak at 2θ = 62.5o [53,55–57]. This 
corresponds with the JCPDS 19-0629 card for magnetite, as IO possesses the (311), (220), 
(511) and (422) peaks that are common to both magnetite and maghemite but lacks of the 
characteristic (210), (211) and (213) peaks of maghemite (JCPDS 39-1346) [53,58]. GO-IO 
displays a distinct (311) peak from the IO, with the other peaks at a lower intensity, showing 
that the magnetite is formed before the hydrothermal treatment, as previously reported [8]. 
GQDs are characteristic of rGO ((002) peak at 2θ = 25.4o) [59]. A-IO is a mixture of 
magnetite, maghemite, and hematite (the α- mineral form of maghemite), with the (311), 
(220), and (422) peaks from the IO, maghemite specific peaks (210), (211), (213), and 
hematite characteristic peaks (021), (110), (024) (JCPDS 33-0664) indicated on the curve 
[53,60]. The presence of hematite is caused by the partial topotactic oxidation of magnetite at 
200 oC during autoclaving [61]. The MGQD curve shows a change in structure from both 
GQD and A-IO. rGO can be identified by the weak (002) peak at 2θ = 21.6o. This peak has 
shifted by 3.8o when compared to the GQD curve, which may stem from the reaction of GO 
and IO during autoclaving that may have altered the crystalline structure (vide infra) [62]. 
The effect of rGO within the MGQDs has caused a reduction in intensity of the (311) and 
(511) peaks from IO, a new (440) peak at 2θ = 76.0o common to magnetite and maghemite, 
and the introduction of a (104) peak at 2θ = 38.3o, a (113) peak at 2θ = 45.5o, and a (300) 
peak at 2θ = 78.1o, all from hematite [53]. 
A further analysis of the structure of the MGQDs and the structural change during 
autoclaving was performed through Raman spectroscopy of GO, IO, GO-IO, GQDs, A-IO 
and MGQDs (Figure 4B). GO can be identified by the G band at 1591 cm-1 (E2g mode) and 
the D band at 1322 cm-1 (A1g) [63]. The IO is a mixture of magnetite and maghemite, with the 
maghemite caused by the local extreme heating of the IO powder by the laser source as it was 
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not identified in the XRD analysis [64,65]. The peak at 300 cm-1 and the broad peak at 660 
cm-1 are assigned to magnetite T2g and A1g, while the peaks at 217, 283 and 401 cm-1 are 
attributed to hematite A1g(1), Eg(2 + 3), and E2g(4) [61,64,66]. The GO-IO spectrum is a 
combination of the characteristic peaks of the GO and IO spectra, again showing the 
successful seeding of IO crystals onto the GO nanosheets. The GQDs can be identified by the 
G band at 1594 cm-1 (E2g mode) and the D band at 1359 cm-1 (a1g), with the ratio of the 
intensities of the D peak to the G peak decreasing relative to GO, showing an increase in the 
sp2 carbon structure of pristine graphene and graphite. A-IO is characterized as a mixture of 
magnetite and hematite, with a magnetite peak at 653 cm-1 [64,67] and a hematite peak at 619 
cm-1 [53,64,67], and with additional goethite (α-FeOOH, the hydrated form of hematite) 
peaks at 924 cm-1 and at 1442 cm-1 [68]. MGQDs can be seen to be magnetite (656 cm-1) 
[64,67], maghemite (broad peak at 500 cm-1) [64,67], hematite (peaks at 218, 287, 402, and 
604 cm-1) and rGO (G peak at 1588 cm-1) [63]. The Raman spectrum of the MGQDs is closer 
to GO-IO than to A-IO. Presumably this is because the IO within the MGQD is magnetite, 
like with GO-IO while the A-IO is mainly composed of maghemite and hematite. The IO of 
MGQD is in the form of a film on the surface of the MGQD as previously described, and 
only has one outer surface exposed to the effects of the hydrothermal treatment, unlike the A-
IO particles which have all the surfaces exposed. This reduces the effect of the hydrothermal 
reaction on the IO on graphene surface, leading to a different chemical composition. 
FT-IR spectra of the nanomaterials are shown in Figure 4C. GO has C-O bonds at 
1043 cm-1, C=C bonds at 1621 cm-1 and C=O bonds at 1720 cm-1. On the IO spectrum, a peak 
for the Fe-O bond is present at 551 cm-1 [8]. For the GO-IO, the synthesis procedure of IO on 
the GO has led to the shift of the C=C aromatic bonds of the GO from 1621 cm-1 to 1593 cm-
1
 and to the creation of O-C=O bonds at 1415 cm-1 [69]. The Fe-O peak has been maintained 
and is at 527 cm-1. The GQD curve shows a reduction in functional groups in comparison to 
GO, with the peaks barely visible on the curve, confirming the reduction of GO to rGO. A-IO 
possesses 622 and 537 cm-1 peaks attributed to Fe-O peaks [66]. MGQDs have 646, 619 and 
462 cm-1 peaks attributed to Fe-O bonds from magnetite, maghemite and hematite, a C=C 
peak at 1564 cm-1 and O-C=O peak at 1406 cm-1 peak that are similar to GO-IO, and 1086 
and 1012 cm-1 peaks attributed to C-Fe bonds confirming the chemical bonding between rGO 
and IO [66].  
Figure 4D shows the TGA curves of the MGQD and its control samples in a nitrogen 
atmosphere. TGA suggests that GO is oxidized graphene (dissociation of epoxide and 
hydroxyl groups at ~200 oC is 23% of the total dry mass). IO has limited dissociation of ~5% 
(similar to magnetite) as it does not possess any functional groups on the surface to be 
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dissociated [70]. GO-IO is a mixture of GO and IO with a main mass loss (~27% of the dry 
mass) at ~780 oC, attributed to the reaction of IO with carbon from rGO to release CO and 
CO2 gases [71]. The GQDs are rGO (reduced mass loss as compared to GO at ~200 oC, 0.5% 
of the total dry mass). A-IO has a major mass loss between 400 and 500 oC (~19% of the dry 
mass) that is attributable to the phase transformation from maghemite to hematite; this phase 
transformation may be accompanied by other transformations such as conversion of 
maghemite to an intermediate product magnetite [53,71–73]. The MGQDs have a minor mass 
loss step at ~720 oC (~3% of the dry mass), which could be due to the reaction between α-
Fe2O3 and carbon of graphene [73], resulting in the release of CO and CO2. The major mass 
loss at ~780 oC in the curve for GO-IO has moved to ~850 oC (with a loss of ~32% of the dry 
mass), which may be the result of autoclaving that has caused phase transformation of the IO 
and the chemical bonding between IO and rGO. 
ICP-MS analysis calculated the quantity of Fe in the MGQD as 448 g kg-1. 
Theoretically, the amount of Fe in Fe2O3 is 70.0 wt.% and in Fe3O4 is 72.4 wt.%. If the 
amount of Fe in the MGQDs is 447.89 g kg-1 (considering the measurement error as 0.11 g 
kg-1 measured for GQDs using the same process), this allows for the mass percentage of IO 
within the MGQDs to be calculated as between 62 – 64 wt.%, with the remainder being the 
rGO. This suggests that IO is the major component of the MGQDs with graphene as the 
minor component. The density of the MGQDs was measured through pycometry as 3.66 (± 
0.006) g cm-3 for MGQDs. In comparison, the density of GQDs was 1.66 (± 0.006) g cm-3, 
slightly higher than that for chitosan-reduced rGO (1.46 g cm-3) [74] because of the absence 
of chitosan in the GQDs. The increase in density of the MGQDs over the value of GQDs is 
due to the higher density of the IO within the MGQD structure, e.g. 4.9 – 5.2 g cm-3 for 
magnetite [41].  
 
3.2 Photoluminescent and magnetic properties 
The photo-physical properties of the nanoparticles were characterized using steady-state UV-
Vis spectroscopy. As shown in Figure 5A, MGQDs and GQDs have absorbance peaks at 270 
nm and 320 nm, with the MGQDs also exhibiting the characteristic absorbance trait of A-IO 
in the wavelength region 400 to 500 nm. The emission characteristics of the MGQDs are 
presented in Figure 5B. Here, excitation of the MGQDs at 320 nm (corresponding to the peak 
in the excitation spectrum) yields an emission spectrum with a peak at 398 nm. This emission 
value is slightly lower than that (420 nm) observed for the GQDs prepared by the same 
hydrothermal method [40]. Quantum yield measurements (using Equation 1) gave a value of 
7.9% for the MGQDs, similar to the published literature for GQDs (5.5-14%) prepared by 
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other groups [20,23,24,75] and slightly lower than the GQDs prepared using the same method 
(9.4%) [40]. These suggest the presence of IO slightly quenches the luminescence of GQDs. 
The photos in the inset confirm the photoluminescence (PL) properties of the MGQDs (right), 
in contrast to the control sample of PBS solution. MGQDs, in a 1 mg ml-1 aqueous 
suspension, have a PL lifetime of 1.9 ns (Figure 5C), similar to GQDs and conventional QDs 
in the literature (range of 1-10 ns) [76–79], and slightly lower than the GQDs prepared using 
the same method (2.3 ns) [40]. 
 
 
 
Figure 5 (A) UV-Vis spectra for GO, IO, GO-IO, GQDs, A-IO and MGQDs (0.3 mg ml-1 
concentration in distilled water); (B) Photoluminescence spectra of MGQDs showing the excitation 
wavelengths versus emission wavelengths; (Inset) Photoluminescent imaging of (left) PBS and (right) 
MGQDs in PBS under 360 nm light; (C) PL lifetime data for MGQDs in an aqueous suspension (1 
mg ml-1). 
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Previously reported GQDs with attached IO (GQD-IOs) did not possess PL properties 
as they synthesized GQDs first and then attached IO [15]. Coating of IO onto the GQDs 
quenched the fluorescence of GQDs, which is similar to the quenching behavior of gold 
nanoparticles bonded to semiconductor QDs [80]. It was theorized that a QD would have its 
fluorescence quenched by a non-radiative energy dissipation process from the bonded 
nanoparticles, and not explicitly through a decrease in the radiative (PL) properties of the QD 
itself [80,81]. In our process the GO-IO was synthesized first and then reduced to MGQDs; 
the reduction procedure broke the GO-IO into small QDs (Figure 2), with the edges of the 
core-GQD within the MGQD now exposed. These edges have a zigzag structure that contain 
triple carbenes [82] which are linked to the electron orbital transition at 320 nm [25], and so 
the PL properties of GQDs are preserved. 
 
Figure 6 (A) Magnetic hysteresis loop of MGQDs and (Inset) digital images of the effect of 
external magnetic stimulation upon MGQD powder, (left) before and (right) after a magnet is 
placed beside it. (B) T2 relaxation time of MGQDs from M.R.I. and (Inset) digital images of 
MGQDs as contrast agents, as a function of increasing Fe concentration. 
The magnetic hysteresis loop of MGQDs (Figure 6A), determined with a SQUID, 
illustrate that they possess no residual magnetization and are superparamagnetic. The 
saturation magnetization of the MGQDs was 7.31 emu g-1, comparable to other magnetic 
nanoparticles (4.62 emu g-1) [8]. As demonstrated in Figure 6A (Inset), the MGQDs can be 
drawn towards a magnet from a resting position. Figure 6B is the T2 relaxation time of 
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MGQDs from M.R.I., with the slope of the relaxation time determined as 4.16 mM-1 s-
1
. In comparison, the slope of the relaxation time of magnetite can vary from 35.48  to 
114 mM-1 s-1 [14,83], maghemite had a slope of 43.3 mM-1 S-1 [84], and gadolinium-doped 
graphene and a GO-IO-manganese oxide nanoparticle had slopes of 108 mM-1 s-1 [85], and 
65.9 − 103 mM-1 s-1 [86], respectively. The relaxation time slopes of nanoparticles that 
contain IO vary due to the different Fe concentrations of the nanoparticles used [14,83,86]. 
Figure 6B (Inset) shows digital images of MGQDs as contrast agents as a function of 
increasing Fe concentration. The results of the PL and magnetic properties tests 
confirm that the MGQDs can potentially be used for dual-modality fluorescent and 
M.R.I. applications. 
 
3.3 Cell viability and imaging 
MGQDs were found to have limited cytotoxicity up to a concentration of 50 µg ml-1 
in MTT cell viability tests (Figure 7A). Suspensions of MGQDs of 20 and 50 µg ml-1 in 
DMEM gave cell viability levels of  70 – 75% compared to cell culture on tissue culture 
plastic at an initial 6 h and 24 h incubation times, suggesting that they have a low 
cytotoxicity. The cell viability values for MGQDs are similar to those recorded for pristine 
IO nanoparticles used for M.R.I. (80% for 50 µg ml-1) [87] and other GQDs reported before 
that are used for fluorescent imaging (70-80%) [20,24,26,27]. There is a dose dependent 
cytotoxic effect with a steep decrease in cell viability from 50 µg ml-1 to 500 µg ml-1. The 
visual effects of acute exposure (6 h incubation) to MGQDs shown in Figures 7B-1 – 7B-6 
for cells which were subsequently cultured for a further 72 h. Cells which had encountered 20 
and 50 µg ml-1 MGQDs grew well showing no long term adverse effects while cells which 
were exposed to concentrations of 100, 200 and 500 µg ml-1 did not recover and increase in 
number over the 72 h (Figures 7B-4 – 7B-6). Many of these cells are seen as the compact, 
white, and circular nodes: an appearance that was previously reported to indicate apoptosis 
[88]. 
The cell viability of nanoparticles at higher concentrations can be improved upon by 
passivation with a coating of a biocompatible organic compound, with amine functionalized 
GQDs [23] and IO functionalized by pullulan [87] significantly improving the cell viability 
of the respective nanoparticles. Chitosan could also act as a passivation agent as previous 
work has shown that chitosan functionalized rGO was more stable in simulated body fluids 
than pristine GO [89], and that chitosan functionalized graphene nanosheets are 
biocompatible and do promote the proliferation of cells [90]. 
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Figure 7 MTT cell viability results for MGQDs treated fibroblast cells. Concentrations used were 20, 
50, 100, 200, and 500 µg ml-1 in DMEM medium and the initial incubation times were 6 h and 24 h. 
Cells were then washed and cultured for a further 72 h before viability was assessed. Bars with the 
same symbols (*, +, -) were statistically similar to each other (p < 0.05). Optical microscopy images 
of the cells were taken 72 h after an initial 6 h incubation with MGQDs. Concentrations used were (B-
1) 0 (control), (B-2) 20, (B-3) 50, (B-4) 100, (B-5) 200, and (B-6) 500 µg ml-1. 
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Figure 8 Optical microscopy images of fibroblast cells after an initial 12 h incubation with MGQDs. 
Concentrations used were (A-C) 50 µg ml-1 and (D-F) 100 µg ml-1. (A) and (D) are the fibroblast cells 
under normal light, and (B) and (E) are under fluorescent light. (C) and (F) are an overlay of the white 
and fluorescent light images. 
Figure 8 shows fibroblast cells under 345 nm irradiation that have been treated with 
(A-C) 50 µg ml-1 and (D-F) 100 µg ml-1 of MGQDs for 12 h. Figure 8 C and F are overlaid 
white light (Figure 8 A and D) and fluorescent light (Figure 8 B and E) images, showing that 
the emission of fluorescent light is from within the cells which suggests that the MGQDs 
entered the cells for both suspension concentrations. The emission is concentration 
dependent, with the emission from the cells stronger when treated with 100 µg ml-1 of 
MGQDs than with 50 µg ml-1; the higher concentration of MGQDs in the suspension allowed 
for more MGQDs to be internalized into the cells, but higher concentrations have been shown 
to be cytotoxic after a long period of incubation (Figure 7A). Nevertheless, at 50 µg ml-1 it is 
still possible to image the nanoparticles. When surface-treated with a passivation agent, 
MGQDs at a higher concentration such as 100 µg ml-1 may also be used without incurring 
toxicity to cells. 
 
3.4 Drug delivery 
The physical bonding of the anesthetic lidocaine hydrochloride (LH) (Figure 9A, inset) onto 
MGQDs to form MGQD-LH is mainly through π-π stacking between the aromatic rings of 
the MGQDs and LH [91]. Figure S2 shows the transposing of LH peaks onto MGQD in FT-
IR (S2A) and Raman (S2B) spectra, showing that the LH is adsorbed to the surface of the 
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MGQDs. A comparison of TGA curves of MGQD-LH with LH and MGQD (Figure 9A) 
allows for the quantity of the drug in MGQD-LH to be estimated as 24 wt.%, giving an 
estimated loading ratio of LH:MGQD of 0.31:1. The drug release profile (Figure 9B) 
determined that the release of LH from MGQD-LH into the PBS achieved ~100% (106.9 ± 
13.1%) of the total drug available, or 5.09 (± 0.63) mg ml-1, at 8 h, after which the test was 
terminated.  
   
 
 
 
 
 
 
Figure 9 (A) TGA curves for MGQD, MGQD-LH and LH (Inset: chemical structure of LH). (B) The 
release of LH from MGQD-LH over the course of 8 h. 
To determine if the diffusion of LH from the MGQD follows Fickian law, Equation 2 
was used [92]: 


   																																																																					
2 
in which Qt is the amount of drug released at the time “t”, QT is the total amount of drug 
released during the experiment, K is the diffusion coefficient and n is the diffusion release 
exponent. It was found that the values of 0.56 µg s-1 and 0.55 for K and n best fit the 
experimental data presented in Figure 9B. This shows that the diffusion of the LH from the 
MGQD was not Fickian but anomalous [93] at pH = 7.4, similar to the diffusion of 
doxorubicin from GO [94] and rhodamine B from GO into a solution of pH = 4.5 [95]. These 
results indicate that a drug can be bonded to the surface of MGQDs and then be gradually 
released from the MGQDs into the body. It has been previously shown in the literature that 
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similar nanoparticles like carbon QDs [28], GO [96] and IO [6] can be extracted from the 
blood and collect in the spleen/bladder to be excreted from the body through urine.  
 
3.5 Photothermal properties 
 
 
 
Figure 10 Temperature increase differential between (A) MGQD suspensions and (B) GQD 
suspensions, and distilled water (control) under NIR 808 nm laser irradiation with varying power. (C) 
CCK-8 cell viability of HeLa cells incubated with 50 µg ml-1 MGQD or GQD suspensions and 
irradiated with a  2.5 W cm-2 NIR laser (wavelength: 808 nm) for 0 min, 20 min, or 30 min. Control 
cells were pristine HeLa cells without QD treatment. 
There is a possibility of using the MGQDs for cancer photothermal therapy, where the 
MGQDs absorb NIR light and convert it to heat that can be used to kill cancer cells locally 
[97]. To assess their potential for this application, suspensions of MGQDs in distilled water, 
together with GQD suspensions and distilled water control sample, were irradiated with a 2, 
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5, and 7.5 W cm-2 NIR laser (wavelength: 808 nm) for a period of time. The results (Figure 
10) show that the temperature of the QD suspension increases with increasing laser power as 
well as QD concentration. After 20 min under 5 W cm-2 irradiation power, it can be seen that 
the temperature of the 50 µg ml-1 MGQD suspension increases by 32.6 oC, compared to 8.9 oC 
for the water control sample and 8.4 oC for the 50 µg ml-1 GQD suspension. This can be 
attributed to the higher absorption of the MGQDs in the NIR range (700-800 nm, Figure 5A) 
than the GQDs; this higher absorption is due to the presence of IO on the MGQDs. After 20 
min, the suspension of 50 µg ml-1 MGQDs at 7.5 W cm-2 achieved a temperature increase of 
46.3 oC; this is comparable to the increase of the 100 µg ml-1MGQD suspension (49.4 oC) 
after 16 min at 5 W cm-2 irradiation. This concentration and laser power dependent result 
shows that the MGQDs can be used as an effective photothermal ablation agent at a low 
concentration that was determined to have low cytotoxicity (Figure 7). The differences in 
suspension concentration, irradiation time, and irradiation power make direct comparisons 
between previously reported photothermal therapy agents difficult. But, generally MGQDs 
compare well to other nanoparticles that are structurally and elementally similar, in particular 
GO-poly(ethylene glycol) (PEG) [13], rGO-PEG [13], GO-IO [9], and IO [14]. MQGDs also 
compare well to other photothermal agents such as carbon nanotubes [98] and gold 
nanoparticles [99].  
The photothermal therapy results suggest that the MGQDs could be potentially used 
for the ablation of tumours, where the presence of MGQDs within the tumour will raise the 
temperature and kill tumour cells locally [97]. MGQDs and GQDs were incubated for 4 h 
with HeLa cells for in vitro photothermal ablation studies (Figure 10C). Under 2.5 W cm-2 
NIR laser irradiation, untreated HeLa cells can be seen to have a similar cell viability, with 
statistical insignificance, to the untreated, non-irradiated cells. This shows that laser 
irradiation alone at this power density will not reduce the viability of the HeLa cells. The 
presence of MGQDs, without irradiation, reduced the cell viability of HeLa cells to 68%, 
compared to 84% for GQDs. These two values are lower than the values for fibroblast cells 
(Figure 7A) due to the different types of cell and incubation conditions used. There are two 
possible causes of this cell-specific susceptibility. MGQDs could have a higher cytotoxic 
effect on HeLa cells than on dermal fibroblast cells because of a higher susceptibility of 
HeLa cells to reactive oxide species than for the fibroblast cells, similar to the differing cell 
viability results for IO when incubated with mesothelioma cells and mice fibroblast that was 
attributed to reactive oxide species damage [100]. This difference may be due also to the rate 
of uptake of the MGQDs into the differing cells [100]; for example, a previous report [101] 
shows the differing rates of uptake for uncoated IO into mouse macrophage and human breast 
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cancer cells. Coating the IO with a biocompatible polymer such as PEG can lower the 
reactive oxide species effect on cells and affect the rate of uptake into cells [101], which may 
increase the cell viability of HeLa cells treated with MGQDs if desired. There is a time 
dependent decrease in cell viability, with a more substantial decrease in cell viability 
occurring when the HeLa cells that were treated with MGQDs were irradiated for 30 min 
than for 20 min (cell viability of 41% versus 62%, respectively). GQDs, under irradiation, did 
not reduce the cell viability of the HeLa cells by as much, achieving a reduction to 83% and 
74% for 20 min and 30 min irradiation time, respectively. This difference between the GQDs 
and the MGQDs is in accordance with the temperature increases from the photothermal 
measurement.  
Previously, QDs such as CuS [102,103] were used as photothermal ablation agents 
under irradiation with a 808 nm laser, with the QDs reducing the viability of HeLa cells [102] 
and of U87 glioblastoma cells [103]. When irradiated for 5 min with a 12 W cm-2 NIR laser, 
around ~65% of the tumour tissue in mice treated with CuS QDs showed signs of necrosis 
[103]. rGO-IO nanosheets achieved the full ablation of 4T1 tumours in mice that were treated 
with a 5 min exposure of 0.5 W cm-2 near-infrared laser irradiation [12]. In comparison to 
these results, our MGQDs are not as efficient as photothermal ablation agents under the laser 
irradiation conditions that we use, but they do offer bimodal imaging, with intrinsic M.R.I 
and fluorescent imaging capability. Also by increasing the laser power density (but still 
within the safe-use range), the photothermal ablation effect of the MGQDs may be improved. 
 
3.5 Biostability 
The stability of the MGQDs in biological fluids, including water, PBS and FCS, was assessed 
and the results are shown in Figure 11. It can be seen that pristine MGQDs partially 
aggregate in distilled water and PBS (pH = 7.4) within 2 h, with larger particles falling to the 
bottom of the container, but the remaining particles remained stable in suspension as the 
quantity of aggregates did not increase with time up to 24 h. The IO on the surface of MGQD 
is hydrophobic [104] and aggregates in water and in PBS. MGQDs in FCS aggregated 
significantly within 2 h, presumably due to the crosslinking of MGQDs by hydrogen bonding 
of the proteins in the FCS with the remaining –COOH groups on MGQD edges [105]. The 
coating of LH onto the MGQD surface has reduced this crosslinking effect and greatly 
improved the biostability of the MGQD over 10 days (Figure 11E), with minimal further 
aggregation of the MGQD-LH after the initial 2 h. In solution, LH maintains a positive ionic 
charge [106], and in FCS the LH coating prevents the MGQDs from aggregating through 
electrostatic repulsion. Coating the MGQDs with another ionic biopolymer, such as chitosan, 
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may also improve the stability of the MGQDs, similar to the improvement afforded to 
chitosan-coated rGO [89], as well as decreasing the cytotoxicity of the MGQDs [90]. 
 
Figure 11 The biostability of (A-C) MGQDs and (D) MGQD-LH suspensions in solutions of (A) 
distilled water, (B) PBS (pH=7.4), (C-D) FCS. (E) MGQD-LH biostability in FCS over 10 days, 
showing that the drug coated MGQD is relatively stable in biological fluid over the test period of 
time. 
4. Conclusions 
The synthesis of MGQDs through the hydrothermal reduction of a water suspension of GO-
IO nanoparticles was shown. The MGQDs were found to be around 45 nm in diameter and 
2.3 nm high from TEM and AFM, with a composition of carbon, oxygen, and iron identified 
from EDS and EELS. Iron oxide was coated onto the graphene surface as a thin film and 
maybe also as individual particles within the bulk MGQDs. A mixture of iron oxides 
(magnetite, maghemite, and hematite) and rGO was formed during the hydrothermal 
reduction process, as determined from XRD, Raman spectroscopy, FT-IR and TGA. MGQDs 
emitted violet light with a wavelength of 398 nm when excited at 320 nm, showing excellent 
photoluminescent properties. They were also superparamagnetic, as determined by magnetic 
hysteresis analysis, and could act as a T2 contrast agent in M.R.I. applications.  
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A safe dosage level of 50 µg ml-1 was determined through cell viability testing with 
dermal fibroblasts for 24 h. Cells which had encountered a concentration of 50 µg ml-1 or 
lower of MGQDs grew well and showed no long term adverse effects. The MGQDs (50 µg 
ml-1 or 100 µg ml-1) entered the cells after incubation for 12 h and could be detected by 
fluorescent imaging. A model drug was successfully bonded to the MGQDs, with a loading 
ratio of 0.31:1 (LH:MGQD), as characterized by FT-IR, Raman spectroscopy and TGA. The 
full release of the drug from the MGQD surface was achieved within 8 h. MGQDs, under 
NIR irradiation, generated a higher temperature than GQDs or distilled water due to the 
presence of iron oxide which is a more effective NIR absorber, and could achieve more 
significant temperature increases at a low concentration and laser power. This higher NIR 
absorption allowed for the MGQDs to reduce the cell viability of cancer cells during in vitro 
laser ablation experiments by a greater amount than was possible with GQDs. Ionic drug 
coated MGQDs were shown to have a better stability in FCS than uncoated MGQDs, which 
showed the coated MGQDs were relatively stable in FCS over the test period (10 days). 
 These results demonstrate that the MGQDs have a low cytotoxicity and they retained 
the photoluminescent properties of GQDs which, in conjunction with the superparamagnetic 
properties from IO nanoparticles, would allow for fluorescent and M.R.I. dual-modality 
imaging in biomedical applications without the need to use an additional fluorescent dye. 
Meanwhile, the MGQDs could be used as a targeted drug carrier via the physical bonding of 
a therapeutic to the MGQDs and the subsequent release of the therapeutic at the desired site 
by external magnetic stimulation, and as an effective potential agent for cancer photothermal 
therapy.  
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